Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors

Background: Entrectinib is an oral, CNS-active, potent inhibitor of tyrosine receptor kinases A/B/C, tyrosine kinase ROS proto-oncogene 1, and anaplastic lymphoma kinase approved for use in patients with solid tumors. We describe 3 clinical studies, including one investigating the single/multiple do...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Invest New Drugs
Hlavní autoři: Meneses-Lorente, Georgina, Bentley, Darren, Guerini, Elena, Kowalski, Karey, Chow-Maneval, Edna, Yu, Li, Brink, Andreas, Djebli, Nassim, Mercier, Francois, Buchheit, Vincent, Phipps, Alex
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2021
Témata:
Phase I Studies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8068699/
https://ncbi.nlm.nih.gov/pubmed/33462752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-01047-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky